On June 16, 2021, the U.S. Food and Drug Administration (FDA) approved avapritinib for the treatment of adult patients with advanced systemic mastocytosis (SM), including aggressive SM, SM with an associated hematological neoplasm, and mast cell leukemia.
Read the FDA announcement.
Read Blueprint Medicines' announcement.
Posted 06/17/2021
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
